Literature DB >> 11998892

The IL-2/IL-15 receptor systems: targets for immunotherapy.

Thomas A Waldmann1.   

Abstract

Although interleukin-2 (IL-2) and -15 (IL-15) share two receptor subunits and many functions, at times they provide contrasting contributions to T-cell-mediated immune responses. IL-2, through its pivitol role in activation-induced cell death (AICD), is involved in peripheral tolerance through the elimination of self-reactive T cells. In contrast, in general IL-15 manifests antiapoptotic actions and inhibits IL-2-mediated AICD. IL-15 stimulates persistence of memory phenotype CD8+ T cells, whereas IL-2 inhibits their expression. Humanized monoclonal antibodies that recognize IL-2Ra, the private receptor for IL-2, are being employed to inhibit allograft rejection and to treat T-cell leukemia/lymphoma. Therapies directed toward inhibiting the actions of the inflammatory cytokine, IL-15, are proposed for an array of autoimmune disorders as well as diseases associated with the retrovirus human T-cell lymphotrophic virus 1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11998892     DOI: 10.1023/a:1014416616687

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  50 in total

1.  Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology.

Authors:  H Ruchatz; B P Leung; X Q Wei; I B McInnes; F Y Liew
Journal:  J Immunol       Date:  1998-06-01       Impact factor: 5.422

2.  Requirement for IRF-1 in the microenvironment supporting development of natural killer cells.

Authors:  K Ogasawara; S Hida; N Azimi; Y Tagaya; T Sato; T Yokochi-Fukuda; T A Waldmann; T Taniguchi; S Taki
Journal:  Nature       Date:  1998-02-12       Impact factor: 49.962

3.  Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.

Authors:  R B Nussenblatt; E Fortin; R Schiffman; L Rizzo; J Smith; P Van Veldhuisen; P Sran; A Yaffe; C K Goldman; T A Waldmann; S M Whitcup
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

4.  A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.

Authors:  J D Burton; R N Bamford; C Peters; A J Grant; G Kurys; C K Goldman; J Brennan; E Roessler; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

5.  The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.

Authors:  R N Bamford; A J Grant; J D Burton; C Peters; G Kurys; C K Goldman; J Brennan; E Roessler; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

6.  Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor.

Authors:  M Noguchi; Y Nakamura; S M Russell; S F Ziegler; M Tsang; X Cao; W J Leonard
Journal:  Science       Date:  1993-12-17       Impact factor: 47.728

7.  Development and proliferation of lymphocytes in mice deficient for both interleukins-2 and -4.

Authors:  B Sadlack; R Kühn; H Schorle; K Rajewsky; W Müller; I Horak
Journal:  Eur J Immunol       Date:  1994-01       Impact factor: 5.532

8.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

Authors:  J Baselga; L Norton; J Albanell; Y M Kim; J Mendelsohn
Journal:  Cancer Res       Date:  1998-07-01       Impact factor: 12.701

9.  Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac.

Authors:  T A Waldmann; J D White; J A Carrasquillo; J C Reynolds; C H Paik; O A Gansow; M W Brechbiel; E S Jaffe; T A Fleisher; C K Goldman; L E Top; R Bamford; E Zaknoen; E Roessler; C Kasten-Sportes; R England; H Litou; J A Johnson; T Jackson-White; A Manns; B Hanchard; R P Junghans; D L Nelson
Journal:  Blood       Date:  1995-12-01       Impact factor: 22.113

10.  The transcription factor interferon regulatory factor 1 (IRF-1) is important during the maturation of natural killer 1.1+ T cell receptor-alpha/beta+ (NK1+ T) cells, natural killer cells, and intestinal intraepithelial T cells.

Authors:  T Ohteki; H Yoshida; T Matsuyama; G S Duncan; T W Mak; P S Ohashi
Journal:  J Exp Med       Date:  1998-03-16       Impact factor: 14.307

View more
  26 in total

1.  Inhibition of immune activation by a novel nuclear factor-kappa B inhibitor in HTLV-I-associated neurologic disease.

Authors:  Unsong Oh; Matthew J McCormick; Dibyadeep Datta; Richard V Turner; Kathryn Bobb; Dileep D Monie; D Robert Sliskovic; Yuetsu Tanaka; Jie Zhang; Jeffrey Meshulam; Steven Jacobson
Journal:  Blood       Date:  2011-01-06       Impact factor: 22.113

2.  Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.

Authors:  Mark P Rubinstein; Marek Kovar; Jared F Purton; Jae-Ho Cho; Onur Boyman; Charles D Surh; Jonathan Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

3.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Authors:  Bibiana Bielekova; Marta Catalfamo; Susan Reichert-Scrivner; Amy Packer; Magdalena Cerna; Thomas A Waldmann; Henry McFarland; Pierre A Henkart; Roland Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

4.  T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules.

Authors:  Navtej Kaur; Osama S Naga; Håkan Norell; Amir A Al-Khami; Matthew J Scheffel; Nitya G Chakraborty; Christina Voelkel-Johnson; Bijay Mukherji; Shikhar Mehrotra
Journal:  Cytokine       Date:  2011-05-23       Impact factor: 3.861

5.  Effects of an agonist interleukin-2/Fc fusion protein, a mutant antagonist interleukin-15/Fc fusion protein, and sirolimus on cardiac allograft survival in non-human primates.

Authors:  Timothy Millington; Maria Koulmanda; Choo Ng; Svjetlan Boskovic; Ognjenka M Nadazdin; Gilles Benichou; Xin Xiao Zheng; Terry B Strom; Joren C Madsen
Journal:  J Heart Lung Transplant       Date:  2012-02-24       Impact factor: 10.247

Review 6.  Daclizumab therapy for multiple sclerosis.

Authors:  Bibiana Bielekova
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

7.  Vaccines with enhanced costimulation maintain high avidity memory CTL.

Authors:  Sixun Yang; James W Hodge; Douglas W Grosenbach; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

8.  The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas.

Authors:  Ewa Bien; Malgorzata Rapala; Malgorzata Krawczyk; Anna Balcerska
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-20       Impact factor: 4.553

Review 9.  Emerging therapies for multiple sclerosis.

Authors:  Paolo A Muraro; Bibiana Bielekova
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

10.  In vitro testing for anti-inflammatory properties of compounds employing peripheral blood mononuclear cells freshly isolated from healthy donors.

Authors:  M Jenny; M Klieber; D Zaknun; S Schroecksnadel; K Kurz; M Ledochowski; H Schennach; Dietmar Fuchs
Journal:  Inflamm Res       Date:  2010-08-26       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.